NasdaqCM USD

Acurx Pharmaceuticals, Inc. (ACXP)

1.0600 +0.1143 (+12.09%)

At close: November 6 at 4:00:01 PM EST

1.0943 +0.0343 (+3.24%)

After hours: November 6 at 5:17:19 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television

ACCESS Newswire 1d ago

AMFN

CAST

BIVI
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

PR Newswire 13d ago

ACXP
+15.71%
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

PR Newswire 18d ago

ACXP
+15.71%
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

ACCESS Newswire 1mo ago

ACXP
+15.71%
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

PR Newswire 1mo ago

ACXP
+15.71%
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

PR Newswire 1mo ago

ACXP
+15.71%
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

GuruFocus.com 2mo ago

ACXP
+15.71%
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

PR Newswire 2mo ago

ACXP
+15.71%
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

PR Newswire 2mo ago

ACXP
+15.71%
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

PR Newswire 3mo ago

ACXP
+15.71%
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

PR Newswire 3mo ago

ACXP
+15.71%
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

PR Newswire 4mo ago

ACXP
+15.71%

Performance Overview

Return	ACXP	S&P 500 (^GSPC)
YTD	-57.43%	+7.76%
1-Year	-78.80%	+9.77%
3-Year	-98.38%	+68.96%

U.S. markets closed

Acurx Pharmaceuticals, Inc. (ACXP)

Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television

Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference